Literature DB >> 22234178

Which is the eligible patient to be treated with pioglitazone? The expert view.

A Avogaro1, M Federici, J Betteridge, R Bonadonna, I W Campbell, G H Schernthaner, B Staels, E Farinaro, G Crepaldi.   

Abstract

Pioglitazone has an important role in the treatment of patients with Type 2 diabetes. The drug can help patients to achieve sustained glycemic control and may delay the requirement for insulin. Pioglitazone may provide benefits beyond its effects on glycemia, with data suggesting it may confer anti-atherosclerotic and cardioprotective properties. Attention should be given to possible side effects relating to class effects of TZD, and selection of appropriate patients to be prescribed pioglitazone will enable optimum benefits to be derived from pioglitazone treatment.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22234178     DOI： 10.1007/BF03346725

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  55 in total

1.  Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

Authors:  Imre Pavo; György Jermendy; Tamas T Varkonyi; Zsuzsa Kerenyi; Andras Gyimesi; Sergej Shoustov; Marina Shestakova; Matthias Herz; Don Johns; Belinda J Schluchter; Andreas Festa; Meng H Tan
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

2.  Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.

Authors:  Rajeev Jain; Kwame Osei; Stuart Kupfer; Alfonso T Perez; Jeff Zhang
Journal:  Pharmacotherapy       Date:  2006-10       Impact factor: 4.705

Review 3.  Rosiglitazone.

Authors:  J A Balfour; G L Plosker
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

4.  Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta.

Authors:  E Zeender; K Maedler; D Bosco; T Berney; M Y Donath; P A Halban
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

5.  Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.

Authors:  Meng Tan; Don Johns; Guillermo González Gálvez; Oscar Antúnez; Guadalupe Fabián; Fernando Flores-Lozano; Sergio Zúñiga Guajardo; Eduardo Garza; Hector Morales; Christopher Konkoy; Matthias Herz
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393

6.  The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Authors:  Erland Erdmann; John A Dormandy; Bernard Charbonnel; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene
Journal:  J Am Coll Cardiol       Date:  2007-04-16       Impact factor: 24.094

7.  Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

Authors:  Rutger W van der Meer; Luuk J Rijzewijk; Hugo W A M de Jong; Hildo J Lamb; Mark Lubberink; Johannes A Romijn; Jeroen J Bax; Albert de Roos; Otto Kamp; Walter J Paulus; Robert J Heine; Adriaan A Lammertsma; Johannes W A Smit; Michaela Diamant
Journal:  Circulation       Date:  2009-04-06       Impact factor: 29.690

Review 8.  Pioglitazone for type 2 diabetes mellitus.

Authors:  B Richter; E Bandeira-Echtler; K Bergerhoff; C Clar; S H Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

9.  Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Authors:  David N Juurlink; Tara Gomes; Lorraine L Lipscombe; Peter C Austin; Janet E Hux; Muhammad M Mamdani
Journal:  BMJ       Date:  2009-08-18

10.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

Authors:  Ioanna Tzoulaki; Mariam Molokhia; Vasa Curcin; Mark P Little; Christopher J Millett; Anthea Ng; Robert I Hughes; Kamlesh Khunti; Martin R Wilkins; Azeem Majeed; Paul Elliott
Journal:  BMJ       Date:  2009-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.